Aimmune's peanut allergy drug meets main goal, shares surge

Aimmune Therapeutics' peanut allergy drug met the main goal of a late-stage study, sending shares sharply higher.
Source: CNBC

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>